Drug delivery systems in the treatment of African trypanosomiasis infections

Expert Opinion on Drug Delivery

Volumn 8, Issue 6, 2011, Pages 735-747

  Kroubi, Maya ^a   Karembe, Hamadi ^b   Betbeder, Didier ^a  

^a UFR3S Pharmacie   (France)

^b CEVA SANTÉ ANIMALE   (France)

Author keywords

African trypanosomiasis; liposomes; nanoparticles; sustained release device; trypanocidal drug

Indexed keywords

ANTITRYPANOSOMAL AGENT; CYCLODEXTRIN; DIMINAZENE ACETURATE; EFLORNITHINE; ETHIDIUM; ISOMETAMIDIUM CHLORIDE; MELARSAMINE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PENTAMIDINE; QUINAPYRAMINE; SURAMIN; UNCLASSIFIED DRUG; VERIBEN;

AFRICAN TRYPANOSOMIASIS; CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NANOENCAPSULATION; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 79956226578     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.574122     Document Type: Review

References (108)

1. WHO.The world health report.World Health Organization, Geneva; 1999
2. Brun R, Blum J, Chappuis F, et al.Human African trypanosomiasis.Lancet 2009;375(9709):148-59
3. Barrett MP, Boykin DW, Brun R, et al.Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.Br J Pharmacol 2007;152(8):1155-71 (Pubitemid 350242432)
4. Burchmore RJ, Ogbunude PO, Enanga B, et al.Chemotherapy of human African trypanosomiasis.Curr Pharm Des 2002;8(4):256-67
5. Barrett MP.Problems for the chemotherapy of human African trypanosomiasis.Curr Opin Infect Dis 2000;13(6):647-51
6. Torreele E, Bourdin Trunz B, Tweats D, et al.Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.PLoS Negl Trop Dis 2006;4(12):e923
7. Yun O, Priotto G, Tong J, et al.NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.PLoS Negl Trop Dis 2010;4(5):e720
8. Date AA, Joshi MD, Patravale VB.Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles.Adv Drug Deliv Rev 2007;59(6):505-21 (Pubitemid 47259228)
9. Miller EN, Allan LM, Turner MJ.Topological analysis of antigenic determinants on a variant surface glycoprotein of Trypanosoma brucei.Mol Biochem Parasitol 1984;13(1):67-81 (Pubitemid 14024947)
10. Jennings FW, Gray GD.Relapsed parasitaemia following chemotherapy of chronic T.brucei infections in mice and its relation to cerebral trypanosomes.Contrib Microbiol Immunol 1983;7:147-54
11. Jennings FW, Hunter CA, Kennedy PG, et al.Chemotherapy of Trypanosoma brucei infection of the central nervous system: the use of a rapid chemotherapeutic regimen and the development of post-treatment encephalopathies.Trans R Soc Trop Med Hyg 1993;87(2):224-6
12. Kinabo LD.Pharmacology of existing drugs for animal trypanosomiasis.Acta Trop 1993;54(3-4):169-83 (Pubitemid 23306682)
13. Williamson J.Chemotherapy and chemoprophylaxis of african trypanosomiasis.Exp Parasitol 1962;12:274-322
14. Pepin J, Milord F, Khonde A, et al.Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.Trans R Soc Trop Med Hyg 1994;88(4):447-52 (Pubitemid 24264546)
15. Burri C.Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 2010;137(14):1987-94
16. Blum J, Nkunku S, Burri C.Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.Trop Med Int Health 2001;6(5):390-400 (Pubitemid 32510076)
17. Carter NS, Berger BJ, Fairlamb AH.Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei.J Biol Chem 1995;270(47):28153-7
18. Senior JC.Fate and behaviour of liposomes in vivo: a review of controlling factors.CRC Crit Rev Ther Drug Carrier Syst 1991;3:123-93
19. Alving CR.Liposomes as drug carriers in leishmaniasis and malaria.Parasitol Today 1986;2(4):101-7 (Pubitemid 17035889)
20. Campbell PI.Toxicity of some charged lipids used in liposome preparations.Cytobios 1983;37(145):21-6 (Pubitemid 13077165)
21. Szoka FC Jr, Milholland D, Barza M.Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.Antimicrob Agents Chemother 1987;31(3):421-9 (Pubitemid 17027132)
22. Kuboki N, Yokoyama N, Kojima N, et al.Efficacy of dipalmitoylphosphatidylcholine liposome against African trypanosomes.J Parasitol 2006;92(2):389-93
23. Souto-Padron T, de Carvalho TU, Chiari E, et al.Further studies on the cell surface charge of Trypanosoma cruzi.Acta Trop 1984;41(3):215-25 (Pubitemid 14009712)
24. Tachibana H, Yoshihara E, Kaneda Y, et al.In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes.Antimicrob Agents Chemother 1988;32(7):966-70
25. Yoshihara E, Tachibana H, Nakae T.Trypanocidal activity of the stearylamine-bearing liposome in vitro.Life Sci 1987;40(22):2153-9 (Pubitemid 17082407)
26. Gruenberg J, Coral D, Knupfer AL, et al.Interactions of liposomes with Trypanosoma brucei plasma membrane.Biochem Biophys Res Commun 1979;88(3):1173-9 (Pubitemid 9210302)
27. Yongsheng Y, Yongchun O, Chengmai R, et al.Trypanocidal value of liposomal diminazene in experimental Trypanosoma brucei evansi infection in mice.Vet Parasitol 1996;61(3-4):349-52 (Pubitemid 26027818)
28. Owens DE, Peppas NA.Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.Int J Pharm 2006;307(1):93-102 (Pubitemid 41773257)
29. Klibanov AL, Maruyama K, Torchilin VP, et al.Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.FEBS Lett 1990;268(1):235-7 (Pubitemid 20233874)
30. Otsuka H, Nagasaki Y, Kataoka K.PEGylated nanoparticles for biological and pharmaceutical applications.Adv Drug Deliv Rev 2003;55(3):403-19 (Pubitemid 36293792)
31. Gref R, Luck M, Quellec P, et al.'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.Colloids Surf B Biointerfaces 2000;18(3-4):301-13 (Pubitemid 30479870)
32. Alexis F, Pridgen E, Molnar LK, et al.Factors affecting the clearance and biodistribution of polymeric nanoparticles.Mol Pharm 2008;5(4):505-15
33. Tsivgoulis GM, Sotiropoulos DN, Ioannou PV.1,2-Dihydroxypropyl-3- arsonic acid: a key intermediate for arsonolipids.Phosphorus, Sulfur and Silicon and the Related Elements 1991;57(3-4):189-93
34. Timotheatou D, Ioannou PV, Scozzafava A, et al.Carbonic anhydrase interaction with lipothioars enites: a novel class of isozymes I and II inhibitors.Met Based Drugs 1996;3(6):263-8 (Pubitemid 27153983)
35. Antimisiaris SG, Ioannou PV, Loiseau PM.In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice.J Pharm Pharmacol 2003;55(5):647-52 (Pubitemid 36705575)
36. Zagana P, Klepetsanis P, Ioannou PV, et al.Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition.Biomed Pharmacother 2007;61(8):499-504 (Pubitemid 47385092)
37. Zagana P, Haikou M, Klepetsanis P, et al.In vivo distribution of arsonoliposomes: effect of vesicle lipid composition.Int J Pharm 2008;347(1-2):86-92 (Pubitemid 350180327)
38. Piperoudi S, Ioannou PV, Frederik P, et al.Arsonoliposomes: effect of lipid composition on their stability and morphology.J Liposome Res 2005;15(3-4):187-97 (Pubitemid 43062267)
39. Piperoudi S, Fatouros D, Ioannou PV, et al.Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles.Chem Phys Lipids 2006;139(2):96-106 (Pubitemid 43183734)
40. Shafer SH, Williams CL.Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.Int J Oncol 2003;23(2):389-400
41. Na HK, Chang CC, Trosko JE.Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH(3), is mediated by inhibition of cytokinesis.Cancer Chemother Pharmacol 2003;51(3):209-15 (Pubitemid 36469949)
42. Lux H, Heise N, Klenner T, et al.Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania.Mol Biochem Parasitol 2000;111(1):1-14
43. Croft SL, Coombs GH.Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs.Trends Parasitol 2003;19(11):502-8 (Pubitemid 37329659)
44. Croft SL, Seifert K, Duchene M.Antiprotozoal activities of phospholipid analogues.Mol Biochem Parasitol 2003;126(2):165-72 (Pubitemid 36255615)
45. Lux H, Hart DT, Parker PJ, Klenner T.Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues.Adv Exp Med Biol 1996;416:201-11 (Pubitemid 126727504)
46. Papagiannaros A, Bories C, Demetzos C, et al.Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.Biomed Pharmacother 2005;59(10):545-50 (Pubitemid 41820384)
47. Atsriku C, Watson DG, Tettey JN, et al.Determination of diminazene aceturate in pharmaceutical formulations by HPLC and identification of related substances by LC/MS.J Pharm Biomed Anal 2002;30(4):979-86 (Pubitemid 35284309)
48. Thunemann AF, Schutt D, Sachse R, et al.Complexes of poly(ethylene oxide)- block-poly(L-glutamate) and diminazene.Langmuir 2006;22(5):2323-8 (Pubitemid 43382869)
49. Soliman GM, Winnik FM.Enhancement of hydrophilic drug loading and release characteristics through micellization with new carboxymethyldextran-PEG block copolymers of tunable charge density.Int J Pharm 2008;356(1-2):248-58
50. Govender T, Stolnik S, Xiong C, et al.Drug-polyionic block copolymer interactions for micelle formation: physicochemical characterisation.J Control Release 2001;75(3):249-58 (Pubitemid 32727256)
51. Prompruk K, Govender T, Zhang S, et al.Synthesis of a novel PEG-blockpoly( aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier.Int J Pharm 2005;297(1-2):242-53 (Pubitemid 40720283)
52. Dou H, Jiang M.Fabrication, characterization and drug loading of pH-dependent multi-morpho- logical nanoparticles based on cellulose.Polym Int 2007;56(7):1206-12 (Pubitemid 47456221)
53. Gibaud S, Gaia A, Astier A.Slow-release melarsoprol microparticles.Int J Pharm 2002;243(1-2):161-6
54. Ben Zirar S, Astier A, Muchow M, et al.Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice.Eur J Pharm Biopharm 2008;70(2):649-56
55. Muller RH, Jacobs C, Kayser O.Nanosuspensions as particulate drug formulations in therapy.Rationale for development and what we can expect for the future.Adv Drug Deliv Rev 2001;47(1):3-19
56. Couvreur P, Dubernet C, Puisieux F.Controlled drug delivery with nanoparticles: current possibilities and future trends.Eur J Pharm Biopharm 1995;41:2-13
57. ISO/TS 27687 IOfSTS.Nanotechnologies - terminology and definitions for nanoobjects- nanoparticle, nanofibre and nanoplate.International Organization for Standardisation 2008
58. Brandenberger C, Rothen-Rutishauser B, Blank F, et al.Particles induce apical plasma membrane enlargement in epithelial lung cell line depending on particle surface area dose.Respir Res 2009;10(1):22
59. Leroueil-Le Verger M, Fluckiger L, Kim YI, et al.Preparation and characterization of nanoparticles containing an antihypertensive agent.Eur J Pharm Biopharm 1998;46(2):137-43 (Pubitemid 28414471)
60. Kim SY, Shin IG, Lee YM.Preparation and characterization of biodegradable nanospheres composed of methoxy poly (ethylene glycol) and DL-lactide block copolymer as novel drug carriers.J Control Release 1998;56(1-3):197-208 (Pubitemid 28511140)
61. Fernandez-Urrusuno R, Fattal E, Rodrigues JM, et al.Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice.J Biomed Mater Res 1996;31(3):401-8 (Pubitemid 26227058)
62. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al.Biodegradable polymeric nanoparticles as drug delivery devices.J Control Release 2001;70(1-2):1-20 (Pubitemid 32144788)
63. Kreuter J, Shamenkov D, Petrov V, et al.Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.J Drug Target 2002;10(4):317-25 (Pubitemid 34746313)
64. Jallouli Y, Paillard A, Chang J, et al.Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro.Int J Pharm 2007;344(1-2):103-9 (Pubitemid 47495981)
65. Chang J, Jallouli Y, Barras A, et al.Chapter 1 - Drug delivery to the brain using colloidal carriers.Prog Brain Res 2009;180:2-17
66. Chang J, Jallouli Y, Kroubi M, et al.Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier.Int J Pharm 2009;379(2):285-92
67. Olbrich C, Gessner A, Schroder W, et al.Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption.J Control Release 2004;96(3):425-35 (Pubitemid 38553921)
68. Olbrich C, Gessner A, Kayser O, et al.Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate.J Drug Target 2002;10(5):387-96
69. Gessner A, Olbrich C, Schroder W, et al.The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles.Int J Pharm 2001;214(1-2):87-91 (Pubitemid 32244084)
70. Loiseau PM, Imbertie L, Bories C, et al.Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.Antimicrob Agents Chemother 2002;46(5):1597-601 (Pubitemid 34415357)
71. Paillard A, Passirani C, Saulnier P, et al.Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers.Pharm Res 2010;27(1):126-33
72. Kroubi M, Dauloued S, Karembe H, et al.Development of a nanoparticulate formulation of diminazene to treat African Trypanosomiasis.Nanotechnology 2010;21(50):505102-10
73. Durand R, Paul M, Rivollet D, et al.Activity of pentamidine-loaded poly (D, L-lactide) nanoparticles against Leishmania infantum in a murine model.Parasite 1997;4(4):331-6 (Pubitemid 127497638)
74. Durand R, Paul M, Rivollet D, et al.Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model.Int J Parasitol 1997;27(11):1361-7 (Pubitemid 27502238)
75. Fusai T, Boulard Y, Durand R, et al.Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model.Parasite 1997;4(2):133-9 (Pubitemid 127498514)
76. Fusai T, Deniau M, Durand R, et al.Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.Parasite 1994;1(4):319-24
77. Paul M, Durand R, Boulard Y, et al.Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice.J Drug Target 1998;5(6):481-90 (Pubitemid 28499682)
78. Kulkarni RK, Moore EG, Hegyeli AF, et al.Biodegradable poly(lactic acid) polymers.J Biomed Mater Res 1971;5(3):169-81
79. Bazile DV, Ropert C, Huve P, et al.Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats.Biomaterials 1992;13(15):1093-102 (Pubitemid 23022908)
80. Makino K, Arakawa M, Kondo T.Preparation and in vitro degradation properties of polylactide microcapsules.Chem Pharm Bull (Tokyo) 1985;33(3):1195-201 (Pubitemid 15104072)
81. Fricker G, Flaig RM.Bdellosomes US 2004062815;2004
82. Flaig RM, Rosenkranz V, Wink M, et al.Ktenate nanoparticles (bdellosomes): a novel strategy for delivering drugs to parasites or tumours.STP Pharm Sci 2005;15(1):59-63 (Pubitemid 40208980)
83. De Deken R, Geerts S, Kageruka P, et al.Chemoprophylaxis of trypanosomiasis, due to Trypanosoma (Nannomonas) congolense, in rabbits using a slow release device containing homidium bromide.Ann Soc Belg Med Trop 1989;69(4):291-6 (Pubitemid 20122322)
84. Geerts S, De Deken R, Kageruka P, et al.Evaluation of the efficacy of a slow release device containing homidium bromide in rabbits infected with Trypanosoma congolense.Vet Parasitol 1993;50(1-2):15-21
85. Kageruka P, Kabore H, Marcotty T, et al.Comparative evaluation of the prophylactic effect of slow release devices containing homidium bromide and isometamidium on Trypanosoma congolense in rabbits.Vet Parasitol 1996;63(3-4):179-85 (Pubitemid 26198248)
86. Geerts S, Kageruka P, De Deken R, et al.Prophylactic effects of isometamidium- and ethidium-sustained release devices against Trypanosoma congolense in cattle.Acta Trop 1997;65(1):23-31 (Pubitemid 27209849)
87. Geerts S, Diarra B, Eisler MC, et al.Extension of the prophylactic effect of isometamidium against trypanosome infections in cattle using a biodegradable copolymer.Acta Trop 1999;73(1):49-58 (Pubitemid 29238111)
88. Lemmouchi Y, Schacht E.Preparation and in vitro evaluation of biodegradable poly(epsilon-caprolactone-co-D,L lactide) (X-Y) devices containing trypanocidal drugs.J Control Release 1997;45:227-33 (Pubitemid 27062974)
89. Lemmouchi Y, Schacht E, Lootens C.In vitro release of trypanocidal drugs from biodegradable implants based on poly (epsilon-caprolactone) and poly(D,L-lactide).J Control Release 1998;55(1):79-85 (Pubitemid 28477566)
90. Lemmouchi Y, Schacht E, Kageruka P, et al.Biodegradable polyesters for controlled release of trypanocidal drugs: in vitro and in vivo studies.Biomaterials 1998;19(20):1827-37 (Pubitemid 28519964)
91. Bray PG, Barrett MP, Ward SA, et al.Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.Trends Parasitol 2003;19(5):232-9 (Pubitemid 36588598)
92. de Koning HP, Anderson LF, Stewart M, et al.The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes.Antimicrob Agents Chemother 2004;48(5):1515-19 (Pubitemid 38544353)
93. Karvonen E, Kauppinen L, Partanen T, et al.Irreversible inhibition of putrescine-stimulated S-adenosyl-Lmethionine decarboxylase by berenil and pentamidine.Biochem J 1985;231(1):165-9 (Pubitemid 16220440)
94. Balana-Fouce R, Garzon Pulido T, Ordonez-Escudero D, et al.Inhibition of diamine oxidase and S-adenosylmethionine decarboxylase by diminacene aceturate (berenil).Biochem Pharmacol 1986;35(9):1597-600 (Pubitemid 16038019)
95. Reinert KE.DNA multimode interaction with berenil and pentamidine; double helix stiffening, unbending and bending.J Biomol Struct Dyn 1999;17(2):311-31
96. Ainanshe OA, Jennings FW, Holmes PH.Isolation of drug-resistant strains of Trypanosoma congolense from the lower Shabelle region of southern Somalia.Trop Anim Health Prod 1992;24(2):65-73
97. Sinyangwe L, Delespaux V, Brandt J, et al.Trypanocidal drug resistance in eastern province of Zambia.Vet Parasitol 2004;119(2-3):125-35 (Pubitemid 38121384)
98. Lun ZR, Min ZP, Huang D, et al.Cymelarsan in the treatment of buffaloes naturally infected with Trypanosoma evansi in south China.Acta Trop 1991;49(3):233-6
99. Boid R, Jones TW, Payne RC.Malic enzyme type VII isoenzyme as an indicator of suramin resistance in Trypanosoma evansi.Exp Parasitol 1989;69(4):317-23 (Pubitemid 19269869)
100. Ndoutamia G, Moloo SK, Murphy NB, et al.Derivation and characterization of a quinapyramine-resistant clone of Trypanosoma congolense.Antimicrob Agents Chemother 1993;37(5):1163-6 (Pubitemid 23141339)
101. Hawking F, Sen AB.The trypanocidal action of homidium, quinapyramine and suramin.Br J Pharmacol Chemother 1960;15:567-70
102. Keiser J, Burri C.Physico-chemical properties of the trypanocidal drug melarsoprol.Acta Trop 2000;74(1):101-4
103. de Melo NF, Grillo R, Rosa AH, et al.Interaction between nitroheterocyclic compounds with beta-cyclodextrins: phase solubility and HPLC studies.J Pharm Biomed Anal 2008;47(4-5):865-9
104. Paulino M, Iribarne F, Dubin M, et al.The chemotherapy of Chagas' disease: an overview.Mini Rev Med Chem 2005;5(5):499-519
105. Pepin J, Milord F.The treatment of human African trypanosomiasis.Adv Parasitol 1994;33:1-47 (Pubitemid 23357084)
106. Wang CC.Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis.Annu Rev Pharmacol Toxicol 1995;35:93-127
107. Vansterkenburg EL, Coppens I, Wilting J, et al.The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action.Acta Trop 1993;54(3-4):237-50 (Pubitemid 23306687)
108. Bacchi CJ, Nathan HC, Hutner SH, et al.Polyamine metabolism: a potential therapeutic target in trypanosomes.Science 1980;210(4467):332-4 (Pubitemid 11208468)